<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8820">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992132</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-103-032</org_study_id>
    <secondary_id>2016-001127-32</secondary_id>
    <nct_id>NCT02992132</nct_id>
  </id_info>
  <brief_title>Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACADIA Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACADIA Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and
      aggression after 12 weeks of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohen-Mansfield Agitation Inventory (CMAI)</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Agitation and Aggression in Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Pimavanserin 34 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pimavanserin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, taken as two tablets, once daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin 34 mg</intervention_name>
    <description>Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth</description>
    <arm_group_label>Pimavanserin 34 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin 20 mg</intervention_name>
    <description>Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth</description>
    <arm_group_label>Pimavanserin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, taken as two tablets, once daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 50 years of age or older

          2. Must be able to understand and provide signed informed consent

               -  from patient, if capable of giving consent

               -  from patient's Legally Authorized Representative (LAR) if patient is not capable
                  of giving consent.

          3. Has a diagnosis of probable AD according to the National Institute on
             Aging-Alzheimer's Association (NIA-AA) guidelines

          4. Meets criteria for agitation according to the International Psychogeriatric
             Association (IPA) guidelines

          5. Lives at home or in an assisted living facility (but can visit the clinic as an
             outpatient). Subjects must have been at their current location for at least 3 weeks
             prior to Screening and plan to remain at the same location for the duration of the
             trial.

          6. Has a designated study partner/caregiver who is in contact with the patient at least
             3 times a week on 3 separate days

          7. Female patients must be of non-childbearing potential or must agree to use an
             acceptable method of contraception or abstinence , for at least 1 month prior to
             randomization, during the study, and 1 month following completion of the study

          8. The patient and caregiver are willing and able to participate in all schedule
             evaluations and complete all required tests

        Exclusion Criteria:

          1. The agitation/aggression is attributable to concomitant medications, environmental
             conditions, substance abuse, or active medical or psychiatric condition

          2. Treatment with an antipsychotic medication within 2 weeks of Baseline visit or 5 half
             lives, whichever is longer

          3. Patient or study partner/caregiver has a medical condition (e.g., hearing, vision
             impairments) that would impair the ability to perform the study assessments.

          4. Has had a myocardial infarction within the last six months

          5. Has a history or symptoms of long QT syndrome

          6. Has a history of a significant psychotic disorder before or during the diagnosis of
             probable Alzheimer's disease (including, but not limited to schizophrenia or bipolar
             disorder)

          7. Patient is bedridden or has any significant medical condition that is unstable and
             would place the patient at undue risk from study drug or study procedures Has a
             sensitivity to pimavanserin or its excipients

          8. Has previously participated in a clinical study with pimavanserin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James M. Youakim, MD</last_name>
    <phone>858-261-2981</phone>
    <email>jyouakim@acadia-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>J. Patrick Kesslak</last_name>
    <phone>858-320-8699</phone>
    <email>pkesslak@acadia-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 13, 2016</lastchanged_date>
  <firstreceived_date>December 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
